Sepp-Lorenzino Laura
CIK 0001777421
EVP, Chief Scientific OfficerDirector
Filings
17
Latest Jun 2, 2026
Issuers covered
3
Showing
17 of 17
Page 1
Track record
8 of 8 open-market trades scored (100% price coverage). Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 8 | 63% | +5.7% | +13.3% | +21.4% | -13.0% |
| 90 days | 8 | 100% | +18.6% | +15.4% | +43.2% | +7.5% |
| 180 days | 8 | 63% | +14.6% | +17.6% | +46.9% | -4.3% |
| 365 days | 8 | 100% | +43.3% | +42.4% | +70.9% | +22.8% |
Issuers
Companies where Sepp-Lorenzino Laura has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | 11 | Jan 7, 2025 |
| TSHA | Taysha Gene Therapies, Inc. | 5 | Jun 2, 2026 |
| LXEO | Lexeo Therapeutics, Inc. | 1 | Apr 30, 2026 |
All filings
17 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|